Resolution of invasive central nervous system aspergillosis in a transplant recipient.
Central nervous system (CNS) aspergillosis carries a uniformly poor prognosis in bone marrow transplant recipients. Amphotericin B can be bound to lipid carriers leading to improvement of its therapeutic index. We describe the successful medical management of CNS aspergillosis in an allogeneic bone marrow transplant patient with administration of Amphotericin B Lipid Complex.
Khoury
H
H
Washington University School of Medicine, Department of Internal Medicine, St Louis, MO 63110-1093, USA.
Adkins
D
D
Miller
G
G
Goodnough
L
L
Brown
R
R
DiPersio
J
J
D000293:Adolescent; D000666:Amphotericin B / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy* / Q000209:etiology; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D004338:Drug Combinations; D004660:Encephalitis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000628:therapy; D010713:Phosphatidylcholines / Q000627:therapeutic use*; D010715:Phosphatidylglycerols / Q000627:therapeutic use*; D011379:Prognosis
D000935:Antifungal Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B